U.S. Markets closed

Diodes Incorporated (DIOD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
51.95-0.30 (-0.57%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close52.25
Open52.97
Bid51.89 x 1200
Ask51.89 x 900
Day's Range51.41 - 53.36
52 Week Range31.51 - 59.70
Volume318,462
Avg. Volume272,196
Market Cap2.675B
Beta (5Y Monthly)N/A
PE Ratio (TTM)21.51
EPS (TTM)2.41
Earnings DateNov 02, 2020 - Nov 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.80
  • These Chip Stocks Jumped On Upbeat Earnings Reports
    Investor's Business Daily

    These Chip Stocks Jumped On Upbeat Earnings Reports

    Amid a mixed week for chip company earnings, two semiconductor stocks got a boost from beat-and-raise reports. SiTime and Synaptics cheered investors with their results and guidance.

  • Barrons.com

    Pfizer Will Help Gilead Sciences Make Its Covid-19 Treatment, Remdesivir

    The drug giant is one of the firms that will manufacture remdesivir, Gilead Sciences’ experimental antiviral that got emergency approval in May as a treatment for Covid-19.

  • MarketWatch

    NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment

    The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. and Incyte Corp. 's Olumiant. Roche Holding AG has also said it will test its rheumatoid arthritis drug in combination with remdesivir.